United States Food and Drug Administration Drug Approval Summary
نویسندگان
چکیده
منابع مشابه
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. Information provided in this summary includes chemistry manufacturing and controls...
متن کاملReport from the FDA United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets
On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinumbased and docetaxel chemotherapies. Information provided in this summary includes chemistry manufacturing and controls,...
متن کاملCCR Perspectives in Drug Approval Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
OnMay15, 2013, theU.S. FoodandDrugAdministration (FDA) approved radiumRa223dichloride (Ra223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castrationresistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA reviewwas based on clinical trial BC1-06, which randomly allocated patients (2:1) to eit...
متن کاملUnited States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
PURPOSE On March 25, 2005, bortezomib (Velcade for Injection; Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.) received regular approval from the U.S. Food and Drug Administration (U.S. FDA) for the treatment of multiple myeloma (MM) progressing after at least one prior therapy. This approval was based on bortezomib's efficacy...
متن کاملEnd points and United States Food and Drug Administration approval of oncology drugs.
PURPOSE To summarize the end points used by the United States Food and Drug Administration (FDA) to approve new cancer drug applications over the last 13 years. MATERIALS AND METHODS The FDA granted marketing approval to 71 oncology drug applications between January 1, 1990, and November 1, 2002. The end points used as the approval basis for each application are presented, and the rationale f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2004
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-03-0564